Showing results (411-420 of 477) with videos related to

Sort By:
Pageof 48
Blood|September 5, 2019
Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular trapsCharlotte Marx, Julia Novotny, Danby Salbeck, et al.
European Heart Journal|June 22, 2019
Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trialDániel Aradi, Lisa Gross, Dietmar Trenk, et al.
JACC. Cardiovascular Interventions|January 8, 2016
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents)Ajay J Kirtane, Puja B Parikh, Thomas D Stuckey, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|February 18, 2015
Impact of body mass index on long-term clinical outcomes after second-generation drug eluting stent implantation: Insights from the international global RESOLUTE programRoberto Diletti, Hector M Garcia-Garcia, Christos Bourantas, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|May 14, 2019
First Report of Edge Vascular Response at 12 Months of Magmaris, A Second-Generation Drug-Eluting Resorbable Magnesium Scaffold, Assessed by Grayscale Intravascular Ultrasound, Virtual Histology, and Optical Coherence Tomography. A Biosolve-II Trial Sub-StudyAlexandre Hideo-Kajita, Hector M Garcia-Garcia, Michael Haude, et al.
JACC. Cardiovascular Interventions|February 23, 2010
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)Gilles Montalescot, Stephen G Ellis, Mark A de Belder, et al.
Circulation. Cardiovascular Interventions|October 18, 2022
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome and High Bleeding RiskShqipdona Lahu, Antonia Presch, Gjin Ndrepepa, et al.
JACC. Cardiovascular Interventions|August 7, 2017
Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry StudyThomas D Stuckey, Ajay J Kirtane, Bruce R Brodie, et al.
The American Journal of Cardiology|December 8, 2015
Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study)Mikkel M Schoos, George D Dangas, Roxana Mehran, et al.
JAMA|October 28, 2010
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysisJessica L Mega, Tabassome Simon, Jean-Philippe Collet, et al.
Pageof 48